Amgen Inc (AMGN)
273.60
+1.69
(+0.62%)
USD |
NASDAQ |
Apr 23, 16:00
273.10
-0.50
(-0.18%)
After-Hours: 20:00
Amgen Enterprise Value: 199.39B for April 22, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
April 22, 2024 | 199.39B |
April 19, 2024 | 197.79B |
April 18, 2024 | 194.48B |
April 17, 2024 | 195.19B |
April 16, 2024 | 196.03B |
April 15, 2024 | 195.96B |
April 12, 2024 | 196.91B |
April 11, 2024 | 198.37B |
April 10, 2024 | 196.46B |
April 09, 2024 | 198.56B |
April 08, 2024 | 197.94B |
April 05, 2024 | 198.34B |
April 04, 2024 | 197.34B |
April 03, 2024 | 200.74B |
April 02, 2024 | 201.70B |
April 01, 2024 | 205.36B |
March 28, 2024 | 206.04B |
March 27, 2024 | 207.10B |
March 26, 2024 | 204.67B |
March 25, 2024 | 204.17B |
March 22, 2024 | 201.67B |
March 21, 2024 | 202.09B |
March 20, 2024 | 200.00B |
March 19, 2024 | 199.29B |
March 18, 2024 | 198.85B |
Date | Value |
---|---|
March 15, 2024 | 197.76B |
March 14, 2024 | 199.19B |
March 13, 2024 | 201.58B |
March 12, 2024 | 201.87B |
March 11, 2024 | 201.24B |
March 08, 2024 | 200.38B |
March 07, 2024 | 199.90B |
March 06, 2024 | 201.90B |
March 05, 2024 | 201.93B |
March 04, 2024 | 203.40B |
March 01, 2024 | 203.90B |
February 29, 2024 | 200.42B |
February 28, 2024 | 202.37B |
February 27, 2024 | 202.92B |
February 26, 2024 | 207.14B |
February 23, 2024 | 208.65B |
February 22, 2024 | 206.50B |
February 21, 2024 | 205.58B |
February 20, 2024 | 205.61B |
February 16, 2024 | 205.71B |
February 15, 2024 | 208.59B |
February 14, 2024 | 209.12B |
February 13, 2024 | 209.34B |
February 12, 2024 | 211.46B |
February 09, 2024 | 209.69B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
108.40B
Minimum
May 31 2019
227.44B
Maximum
Feb 01 2024
157.59B
Average
158.16B
Median
Enterprise Value Benchmarks
Gilead Sciences Inc | 101.06B |
Johnson & Johnson | 365.75B |
Eli Lilly and Co | 717.71B |
Merck & Co Inc | 349.51B |
Vertex Pharmaceuticals Inc | 92.07B |
Enterprise Value Related Metrics
Net Income (Quarterly) | 767.00M |
Revenue (Quarterly) | 8.196B |
Total Expenses (Quarterly) | 6.925B |
EPS Diluted (Quarterly) | 1.42 |
Gross Profit Margin (Quarterly) | 62.03% |
Profit Margin (Quarterly) | 9.36% |
Earnings Yield | 4.57% |
Operating Earnings Yield | 5.37% |
Normalized Earnings Yield | 4.565 |